Genmab A/S
F:GE91
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Genmab A/S
F:GE91
|
DK |
|
SAP SE
TSX:SAPS
|
DE |
Intrinsic Value
Is GE91 undervalued or overvalued?
See the intrinsic value estimate for 
Genmab A/S and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Genmab A/S Does
Genmab A/S is a biotechnology company that discovers and develops antibody medicines for cancer and other serious diseases. It does not make broad consumer products; instead, it focuses on turning lab-made antibodies into drug candidates that can be tested, approved, and sold by itself or with larger drugmakers.
- Headquarters
- Denmark DK
- Employees
- 3 088
- IPO date
- Oct 1, 2000
Genmab A/S has a narrow economic moat
Patents on Genmab’s antibody medicines and technologies make it harder for rivals to copy protected treatments, while partner sales allow Genmab to earn royalties from some of them. This protection supports its position in markets where approved medicines compete for patients.
Read the full moat analysis
Revenue & Expenses Breakdown
Genmab A/S
Earnings Waterfall
Genmab A/S
The intrinsic value for Genmab A/S (GE91) under the Base Case is hidden EUR.
Compared with the current market price of 48.4 EUR, the stock appears hidden.
